![]() |
Name |
xylariaone A2
|
Molecular Formula | C18H16O4 | |
IUPAC Name* |
4,5-dihydroxy-3-methoxy-2,5-diphenylcyclopent-2-en-1-one
|
|
SMILES |
COC1=C(c2ccccc2)C(=O)C(O)(c2ccccc2)C1O
|
|
InChI |
InChI=1S/C18H16O4/c1-22-15-14(12-8-4-2-5-9-12)16(19)18(21,17(15)20)13-10-6-3-7-11-13/h2-11,17,20-21H,1H3/t17-,18-/m0/s1
|
|
InChIKey |
OPEADBKTXWEBIK-ROUUACIJSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 296.32 | ALogp: | 1.9 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.913 |
Caco-2 Permeability: | -4.846 | MDCK Permeability: | 0.00007650 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.903 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.001 |
Blood-Brain-Barrier Penetration (BBB): | 0.635 | Plasma Protein Binding (PPB): | 90.06% |
Volume Distribution (VD): | 1.072 | Fu: | 11.30% |
CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.113 |
CYP2C19-inhibitor: | 0.059 | CYP2C19-substrate: | 0.933 |
CYP2C9-inhibitor: | 0.062 | CYP2C9-substrate: | 0.037 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.111 |
CYP3A4-inhibitor: | 0.087 | CYP3A4-substrate: | 0.929 |
Clearance (CL): | 3.154 | Half-life (T1/2): | 0.104 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.344 |
Drug-inuced Liver Injury (DILI): | 0.981 | AMES Toxicity: | 0.29 |
Rat Oral Acute Toxicity: | 0.925 | Maximum Recommended Daily Dose: | 0.034 |
Skin Sensitization: | 0.151 | Carcinogencity: | 0.046 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.053 |
Respiratory Toxicity: | 0.118 |